Group-Based Intervention to Improve Mental Health and Adherence Among Youth Living With HIV in Low Resource Settings

IMPAACT 2016 - Evaluating a Group-Based Intervention to Improve Mental Health and Antiretroviral Therapy (ART) Adherence Among Youth Living With HIV in Low Resource Settings

IMPAACT 2016 is a multi-site, two-arm, individually randomized, controlled study to evaluate whether an Indigenous Leader Outreach Model (ILOM) of trauma-informed cognitive behavioral therapy (TI-CBT) delivered by Indigenous Youth Leaders (IYL) is associated with improved mental health outcomes and ART adherence among youth living with HIV in resource-limited settings. The intervention is adapted to the local context through advance conduct of focus groups and pilot testing.

Study Overview

• Status: Recruiting
• Conditions: HIV-1-infection
• Intervention / Treatment: Behavioral: TI-CBT Intervention Arm; Behavioral: Discussion Control Arm

Detailed Description

IMPAACT 2016 is a multi-site, two-arm, individually randomized, controlled study to evaluate whether an Indigenous Leader Outreach Model (ILOM) of trauma-informed cognitive behavioral therapy (TI-CBT) delivered by Indigenous Youth Leaders (IYL) is associated with improved mental health outcomes and ART adherence among youth living with HIV in resource-limited settings. To adapt the intervention for the local context, the trial will be preceded by an adaption of the TI-CBT intervention at each site using the "ADAPT-ITT" model, which includes focus groups and pilot tests. In the randomized study, youth will be individually randomized to either the TI-CBT Intervention Arm or the Discussion Control Arm. Participants will meet as a group within their randomized arm and receive multiple group sessions within an eight-week period. Each group will include an average of eight youth for an approximate total of 192-256 youth in the Randomized Trial (96-128 youth per arm). TI-CBT and Discussion Control groups in each arm will be mixed-gender unless it is determined necessary to have single-gender groups during the focus group. Caregivers (as available and with youth permission) will be assigned to the same study arm as their youth. Caregivers will meet as a group for two caregiver-specific sessions on two separate weeks and separate from their youth group sessions. Youth and caregivers will complete a follow-up visit immediately after their last group session and two additional follow-up visits at six and 12 months. Youth and caregivers will also receive one two-hour booster group session consistent with their assigned study arm immediately after the six-month evaluations. The booster sessions are intended to enhance treatment effects and increase sustainability. Once all participants have completed their six-month evaluations, data from these evaluations will be analyzed to determine the short-term effects of the intervention. Additional analyses to assess the longer-term effects of the intervention, including the effects of the booster group session, will be performed after the completion of follow-up.

• Study Type: Interventional
• Enrollment (Estimated): 256
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Nicole Montañez, MSW; Phone Number: 11844 919-544-7040; Email: nmontanez@fhi360.org
• Study Contact Backup: Name: Jennifer Libous, MS; Phone Number: 18131 202-884-8131; Email: jlibous@fhi360.org

Study Locations

• Botswana
  • Gaborone, Botswana
    • Recruiting
    • Gaborone Prevention/Treatment Trials CRS 12701
    • Contact: Gaerolwe Masheto, MD; Phone Number: 2673975999; Email: gmasheto@bhp.org.bw
  • Molepolole, Botswana
    • Recruiting
    • Molepolole Prevention/Treatment Trials CRS 12702
    • Contact: Gaerolwe Masheto, MD; Phone Number: 2673975999; Email: gmasheto@bhp.org.bw
• Malawi
  • Blantyre, Malawi
    • Recruiting
    • College of Medicine CRS 30301
    • Contact: Limbika Senganimalunje; Phone Number: 265993662154; Email: limbika@jhu.medcol.mw
  • Lilongwe, Malawi
    • Recruiting
    • University of North Carolina Lilongwe CRS 12001
    • Contact: Portia Kamthunzi; Phone Number: 265999553034; Email: pkamthunzi@unclilongwe.org
• South Africa
  • Soweto, South Africa
    • Recruiting
    • Soweto IMPAACT CRS 8052
    • Contact: Janice Buckley, MBChB/FCPsyc; Email: buckleyj@phru.co.za
• Zimbabwe
  • Chitungwiza, Zimbabwe
    • Recruiting
    • St. Mary's CRS 30303
    • Contact: Tsungai Chipato, MBChB/MSE; Phone Number: 2634704890; Email: tchipato@zol.co.zw
  • Harare, Zimbabwe
    • Recruiting
    • Harare Family Care CRS 31890
    • Contact: Hilda Mujuru, MBChB/MSc; Phone Number: 2634791631; Email: hmujuru@iwayafrica.co.zw; drhamujuru@gmail.com
  • Harare, Zimbabwe
    • Recruiting
    • Seke North CRS 30306
    • Contact: Tsungai Chipato, MBChB/MSE; Phone Number: 2634704890; Email: tchipato@zol.co.zw

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 15 years to 19 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria - For Youth Participants:

• At screening, 15-19 years old.
• If of legal age to provide independent informed consent as determined by site Standard Operating Procedures (SOPs) and consistent with site IRB/EC policies and procedures: potential youth participant is willing and able to provide written informed consent for study participation.
• If not of legal age to provide independent informed consent: Parent or guardian is willing and able to provide written informed consent for study participation and potential youth participant is willing and able to provide written informed assent for study participation.
• Confirmed HIV-infection based on documented testing of two samples collected at different time points as documented in medical records or by confirmatory testing.
• At screening, aware of his or her HIV infection, as confirmed by Investigator of Record or designee.
• At screening, has been prescribed ART for a minimum of 24 weeks prior to screening based on medical record documentation.

• At screening, meets at least one of the following indicators of moderate to severe mental health symptomology:

  • Patient Health Questionnaire-9 (PHQ-9) score ≥ 10
  • General Anxiety Disorder-7 (GAD-7) score ≥ 10
  • UCLA Post-Traumatic Stress Disorder-Reaction Index (UCLA PTSD-RI) score > 35

Inclusion Criteria - For Caregiver Participants:

• Caregiver, defined as a biological parent, legal guardian, or person who provides emotional, psychological and/or informational care to a youth taking part in the Randomized Trial, as identified by the youth, and for whom the youth has provided written permission to participate in the study.
• Of legal age to provide independent consent and willing and able to provide written informed consent for study participation.

Exclusion Criteria - For Youth Participants:

• At entry, participating in a study delivering a mental health or ART adherence intervention.
• Has prior participation in an IMPAACT 2016 Focus Group or Pilot Test
• Any other condition, adverse social situation or cognitive impairment that, in the opinion of the site investigator, would preclude informed assent and informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Exclusion Criteria - For Caregiver Participants:

Has prior participation in an IMPAACT 2016 Focus Group or Pilot Test.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TI-CBT Intervention Arm; In the Randomized Trial, youth participants will be randomized in a 1:1 ratio with their caregivers to one of two study arms. One arm is the TI-CBT intervention arm consisting of: six 2-hour TI-CBT group sessions lead by Indigenous Youth Leaders (IYL) during weeks 1 - 6 and one 2-hour booster group session at 6-months. The caregivers (willing to participate with youth permission) for youth who are enrolled into the TI-CBT arm will be enrolled onto the same arm, and receive two 2-hour group sessions led by adult study staff during weeks 1-6 and one 2-hour booster group session at 6-months. The youth and caregiver sessions are held separately.	Behavioral: TI-CBT Intervention Arm; TI-CBT teaches techniques and ways to manage distress through psychosocial health education, cognitive restructuring, and "mastery of trauma", which refers to the process by which survivors of psychological trauma work through the traumatic experience in a meaningful way, and are able to move on with life. TI-CBT addresses both the trauma of learning one has HIV and the trauma associated with managing a chronic and stigmatized illness. The intervention highlights links between HIV and traditional gender roles, gender inequities, and gender based violence. Finally, the relaxation training teaches youth strategies to relax and these are integrated at the beginning and end of each session. TI-CBT Youth and Caregiver Intervention Manuals are distributed to sites for translation, backtranslation, and cultural adaptation in preparation for the Randomized Trial.
Active Comparator: Discussion Control Arm; Arm two is the discussion control arm consisting of: six 2 hour discussion group sessions lead by IYL during weeks 1-6 and one 2-hour booster discussion group session at 6 months. The caregivers (willing to participate with youth permission) for youth randomized to the discussion control arm will have two 2-hour discussion group sessions led by adult study staff during weeks 1-6 and one 2-hour booster discussion group session at 6 months. The youth and caregiver sessions are held separately.	Behavioral: Discussion Control Arm; Each youth discussion control group session will be led by IYL and each caregiver discussion control group will be led by adult study staff. Discussion topics will be selected by youth and caregivers in the group as applicable. Discussion Control group session will take place at a separate time from TI-CBT youth group sessions in attempt to minimize contamination. To note, participant and caregiver group sessions are always held separately.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient Health Questionnaire-9	(PHQ-9, measure of depression: range 0-27, higher=worse)	at 6-months
General Anxiety Disorder-7	(GAD-7, measure of anxiety: range 0-21, higher=worse)	at 6-months
UCLA Post-Traumatic Stress Disorder-Reaction Index	(UCLA PTSD-RI, measure of TPSD: range 0-51, higher=worse)	at 6-months
Composite mental health measure	(measure of combined mental health issues: PHQ-9, GAD-7, and UCLA PTSD-RI scores will be standardized to have mean=0, standard deviation=1, and then summed; higher=worse)	at 6-months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient Health Questionnaire-9	(PHQ-9, measure of depression: range 0-27, higher=worse)	after initial treatment completion (an average of 6 weeks)
General Anxiety Disorder-7	(PHQ-9, measure of depression: range 0-27, higher=worse)	after initial treatment completion (an average of 6 weeks)
UCLA Post-Traumatic Stress Disorder-Reaction Index	(UCLA PTSD-RI, measure of TPSD: range 0-51, higher=worse)	after initial treatment completion (an average of 6 weeks)
Composite mental health measure	(measure of combined mental health issues: PHQ-9, GAD-7, and UCLA PTSD-RI scores will be standardized to have mean=0, standard deviation=1, and then summed; higher=worse)	after initial treatment completion (an average of 6 weeks)
ART Adherence	Self-report - Wilson 3-item scale (range 0-100, higher=better)	after initial treatment completion (an average of 6 weeks), and at 6-months
Viral Load	HIV-1 RNA	after initial treatment completion (an average of 6 weeks), and at 6-months

Collaborators and Investigators

• Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
• Collaborators: National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH)
• Investigators: Study Chair: Geri Donenberg, PhD, University of Illinois at Chicago; Study Chair: Dorothy Dow, MD, MSc, Duke University; Principal Investigator: Suad Kapetanovic, MD, University of Southern California

Publications and helpful links

Helpful Links

• IMPAACT 2016 web page

Study record dates

Study Major Dates

• Study Start (Actual): November 11, 2023
• Primary Completion (Estimated): March 30, 2025
• Study Completion (Estimated): September 30, 2025

Study Registration Dates

• First Submitted: July 2, 2019
• First Submitted That Met QC Criteria: July 16, 2019
• First Posted (Actual): July 18, 2019

Study Record Updates

• Last Update Posted (Actual): March 13, 2024
• Last Update Submitted That Met QC Criteria: March 11, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: Adherence; Mental Health; Trauma-Informed Cognitive Behavioral Therapy
• Other Study ID Numbers: IMPAACT 2016; DAIDS ID #38506 (Other Identifier: DAIDS/NIAID/NIH)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Individual participant data that underlie results in the publication, after deidentification.
• IPD Sharing Time Frame: Beginning three months following publication and available throughout period of funding of the International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Network by NIH.

IPD Sharing Access Criteria

Data will be shared with researchers who provide a methodologically sound proposal for use of the data that is approved by the IMPAACT Network.

Types of Analyses: Specifically for the types of analyses needed to achieve aims in the proposal approved by the IMPAACT Network.

Mechanism: Researchers may submit a request for access to data using the IMPAACT "Data Request" form at: https://www.impaactnetwork.org/resources/study-proposals.htm. Researchers of approved proposals will need to sign an IMPAACT Data Use Agreement before receiving the data.

• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No